Volume : 09, Issue : 12, December – 2022

Title:

67.NEW RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF SERTRALINE AND ALPRAZOLAM IN PHARMACEUTICAL DOSAGE FORM
‬

Authors :

H. Padmalatha

Abstract :

Objective: A New method was established for simultaneous estimation of Sertraline and Alprazolam by RP-HPLC method.
Methods: Chromatographic separations were carried using HPLC equipped with Auto Sampler and PDA Detector, Inertsil ODS (1.7 x 50 mm, 3m) column with a mobile phase composition of Methanol: TEA Buffer (65:35 v/v) have been delivered at a flow rate of 1ml/min and the detection was carried out using waters HPLC auto sampler, separation module 2695 HPLC system with PDA detector at wavelength 230 nm.
Results: The retention time for Sertraline and Alprazolam were 2.152 and 3.64 minute respectively. The correlation coefficient values in linearity were found to be 0.999 and concentration range 10-50 μg/ml for Sertraline and 20-100 µg/ml for Alprazolam respectively. For accuracy the total recovery was found to be 100.37 % and 100.34 % for Sertraline and Alprazolam. LOD and LOQ for Sertraline 0.9 and 1.2 μg/mL, LOD and LOQ for Alprazolam 2.7 and 3.6 μg/mL.
Conclusion: The results of study showed that the proposed RP‐HPLC method is a simple, accurate, precise, rugged, robust, fast and reproducible, which may be useful for the routine estimation of Sertraline and Alprazolam in pharmaceutical dosage form.
Keywords: Sertraline, Alprazolam, RP‐HPLC, Simultaneous estimation.

Cite This Article:

Please cite this article in press H. Padmalatha , New RP-HPLC Method Development And Validation For Simultaneous Estimation Of Sertraline And Alprazolam In Pharmaceutical Dosage Form., Indo Am. J. P. Sci, 2022; 09(12).

Number of Downloads : 10

References:

1. Murdoch D, McTavish D: Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 1992 Oct;44(4):604-24. (PubMed ID 1281075)
2. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C: Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006117. doi: http://dx.doi.org/10.1002/14651858.CD006117. (PubMed ID 20091586)
3. Rang, H. P. and Dale, M. M. (2012). Rang and Dale’s Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. (ISBN 978-0-7020-3471-8)
4. FDA Approved Drug Products: XANAX XR (alprazolam) extended-release tablets
5. Scott S, Aricescu AR: A structural perspective on GABAA receptor pharmacology. Curr Opin Struct Biol. 2019 Feb; 54:189-197. doi: 10.1016/j.sbi.2019.03.023. Epub 2019 May 23. (PubMed ID 31129381)
6. Olsen RW: GABAA receptor: Positive and negative allosteric modulators. Neuropharmacology. 2018 Jul 1;136(Pt A):10-22. doi: 10.1016/j.neuropharm.2018.01.036. Epub 2018 Jan 31. (PubMed ID 29407219)
7. Pathak; et al. Journal of AOAC International, November 2008, 91 (6), 1344-1353.
8. P Perez-Lozano; et al. Journal of Pharmaceutical and Biomedical Analysis, 10 March 2004, 34 (5), 979–987.
9. Alessia Ferrarini ; et al. Journal of pharmaceutical and biomedical analysis, 10 October 2010, 53(2), 122–129.
10. G.Tulja rani; et al.A Journal of Pharmacy Research, January 2011, 4(2), 358-360.
11. Amir Farshchia; et al. Iranian Journal of Pharmaceutical Sciences Summer 2009, 5(3), 171-178.